Abstract

Mevalonate kinase deficiency (MKD), a very rare autosomal recessive autoinflammatory disease with multiple organ involvement, presents clinically as hyperimmunoglobulinemia D syndrome (HIDS), a less severe phenotype and more common form, and mevalonic aciduria (MVA), a more severe phenotype and rare form. MKD is characterized by recurrent febrile attacks that are frequently accompanied by lymphadenopathy, gastrointestinal symptoms, arthralgia, myalgia, skin rash, and aphthous ulcers. Patients with MVA also have intrauterine growth retardation, congenital defects (cataracts, shortened limbs, and dysmorphic craniofacial features), neurological disease, and failure to thrive. Mean age at onset of symptoms is within the first year of life. There is a delay by several years between symptom onset and diagnosis, which is in part attributable to the initial misdiagnosis due to the rarity and nonspecific clinical manifestations of disease. The frequency of recurrent febrile attacks is highest in childhood and gradually decreases after adolescence. MKD is associated with rare long-term complications such as type AA amyloidosis, joint contractures, abdominal adhesions, renal angiomyolipoma, and severe pneumococcal infections. Frequent febrile attacks significantly impair several aspects of patients’ and caregivers’ quality of life, with an adverse impact on patients’ daily activities, education, and employment. Lifespan is generally normal for HIDS whereas MVA can be fatal in early childhood.

Highlights

  • Mevalonate kinase deficiency (MKD) is a very rare, autosomal recessive autoinflammatory disease with multiple organ involvement [1, 2]

  • This review summarized the existing literature related to MKD natural history

  • The analysis found a sensitivity of 92 %, a specificity of 90 %, a positive predictive value of 71 %, and a negative predictive value of 98 %, further indicating that the urinary mevalonic acid measurement is a reasonable biomarker to screen patients for mevalonate kinase (MVK) genetic testing and enzyme assay [37]

Read more

Summary

Background

Mevalonate kinase deficiency (MKD) is a very rare, autosomal recessive autoinflammatory disease with multiple organ involvement [1, 2]. Clinical features and progression of disease While the average age at onset of symptoms of MKD is within the first year of life, and before age 5 for the vast majority of the patients (2), it could vary from the first week of life to 20 years [2, 8,9,10] (Table 1). The median age at diagnosis is about 8 to 10 years, suggesting a delay by several years between symptom onset and diagnosis This can be in part attributable to the initial misdiagnosis due to its rarity and the nonspecific nature of the clinical disease manifestations [8, 10, 26].

Study design Study period
Literature
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call